{"id":"NCT01246791","sponsor":"Nobelpharma","briefTitle":"Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers","officialTitle":"A Single Dose Pharmacokinetics Study of NPC-01 (1mg Norethisterone and 0.02mg Ethynyl Estradiol) in Healthy Female Volunteers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2010-11-23","resultsPosted":"2014-06-17","lastUpdate":"2025-06-17"},"enrollment":12,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Healthy"],"interventions":[{"type":"DRUG","name":"NPC-01","otherNames":["Norethisterone and Ethinyl Estradiol"]}],"arms":[{"label":"NPC-01","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the pharmacokinetic profiles of norethisterone and ethinyl estradiol after single oral administration of NPC-01 in healthy female volunteers.\n\nPharmacokinetics of norethisterone and ethinyl estradiol will be evaluated on the basis of AUC, Cmax, tmax, t1/2, MRT, kel and AUCâˆž.","primaryOutcome":{"measure":"Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01","timeFrame":"0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01","effectByArm":[{"arm":"NPC-01","deltaMin":69.183,"sd":36.316}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Metrorrhagia","Headache","Blood iron decreased","White blood cell count decreased"]}}